Novartis Venture Fund
Profile, fund size and portfolio
Novartis Venture Fund is the corporate venture arm of Novartis, a pharmaceutical and biotech company. It was founded in 1996 and is based in Basel, Switzerland. It invests from seed to Series A. Sectors it names: biotech and life sciences.
Every figure links to its source
Snapshot
Data behind this graphic
| Measure | Value | Unit | Kind | Source |
|---|---|---|---|---|
| Headline size | USD 750M | AUM or capital under management | Stated by the firm or its parent | S3 |
| Companies backed | 40+ | companies | Stated by the firm | S1 |
| Companies on the firm's portfolio page | 31 | companies | Counted from the firm's own list | S3 |
Sources: S3 Novartis Venture Fund portfolio; S1 Novartis Venture Fund home.
Where it invests and who leads it
Geography
- Headquarters
- Basel, Switzerland
- Offices
- Basel, Switzerland
- Cambridge, United States
Investment regionsS3S1
Key facts
| Fact | Value | Status | Source |
|---|---|---|---|
| Parent company | Novartis | Single source | S8 |
| Parent industry | Pharmaceuticals and biotech | Single source | S8 |
| Founded | 1996 | Single source | S4 |
| Headquarters | Basel, Switzerland | Single source | S2 |
| Status | Active | Single source | S1 |
| Headline size | USD 750M (AUM or capital under management) | Single source | S3 |
| Companies backed | 40+ | Single source | S1 |
| Stages | Seed, Series A | Single source | S3 |
Notable outcomes
IPOs and acquisitions of portfolio companies. Price shown only where published.
| Company | Type | Year | Acquirer or exchange | Source |
|---|---|---|---|---|
| Acorda Therapeutics | IPO | 2006 | NASDAQ: ACOR | S4 |
| Aeglea Biotherapeutics | IPO | 2016 | NASDAQ: AGLE | S4 |
| Aerpio Therapeutics | IPO | 2017 | NASDAQ:ARPO | S4 |
| Aileron Therapeutics | IPO | 2017 | NASDAQ | S4 |
| Akebia Therapeutics | IPO | 2014 | NASDAQ: AKBA | S4 |
| Akouos | IPO | 2020 | NASDAQ: AKUS | S4 |
| Altimmune, Inc. | IPO | 2017 | NASDAQ: ALT | S4 |
| Annexon | IPO | 2020 | NASDAQ:ANNX | S4 |
| Adicet Bio | IPO | 2020 | NASDAQ: ACET | S4 |
| Bicycle Therapeutics | IPO | 2019 | NASDAQ: BCYC | S4 |
| BioNano Genomics | IPO | 2018 | NASDAQ: BNGO | S4 |
| Celladon | IPO | 2014 | NASDAQ: CLDN | S4 |
| Cellerix | IPO | 2011 | NYSE: TIG | S4 |
| CombinatorRx | IPO | 2005 | NASDAQ: CRXX | S4 |
| Cytos Biotechnology | IPO | 2002 | S4 | |
| Evolva Holding | IPO | 2010 | SIX: EVE | S4 |
| Forma Therapeutics | IPO | 2020 | NASDAQ: FMTX | S4 |
| Galera Therapeutics | IPO | 2019 | NASDAQ:GRTX | S4 |
| Gensight Biologics | IPO | 2016 | S4 | |
| Idenix Pharmaceuticals | IPO | 2004 | NASDAQ: IDIX | S4 |
For founders
Portfolio
The firm's portfolio page lists 31 companies.S3
The firm also states 40+ companies backed. The page list and the stated total measure different things.S1
Every company on the Novartis Venture Fund list
31 companies, as listed on the firm's own website.S3 Read the firm's list.
- Amphista Therapeutics
- Anaveon
- Aravax
- Artios Pharma
- Arvada Therapeutics
- AstronauTx
- Atalanta
- Averna Therapeutics
- CatalYm
- Citryll
- Enterprise Therapeutics
- Epi Biologics
- Epsilogen
- Fore Biotherapeutics
- FoRx Therapeutics
- GentiBio
- Granite Bio
- HYKU Biosciences
- Kynexis
- LoQus23
- Mediar Therapeutics
- NRG Therapeutics
- ONL Therapeutics
- Protego
- RhyGaze
- Salvina
- Seawolf
- Sidewinder Therapeutics
- SpliceBio
- Tagworks Pharmaceuticals
- Vivet Therapeutics
History
- Novartis Venture Fund founded (IPO exits page: since its foundation in 1996).S4
Official pages
Read the firm's own pages for current information.
Sources
Disclaimer and corrections
Not affiliated. This page is not affiliated with, endorsed by or sponsored by Novartis Venture Fund or any company named on it. Names and trademarks belong to their owners. Informational only. This is a public-source reference. It is not investment, legal or tax advice and not an offer or solicitation. Sources. Each figure names its source. Figures may have changed. Please read the firm's official pages, linked above. Corrections and takedown. To report an error or ask for a change or removal, use the correction form or email Richard@CorporateVentureCapital.com.
Spotted a mistake? Report a correction.